Skip to content

Clinical observation on the intervention of medical weight management program in obese patients

Clinical observation on the intervention of medical weight management program in obese patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017463
Enrollment
Unknown
Registered
2018-07-31
Start date
2018-07-31
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Intensive intervention group:Physicians, nutritionists, and health managers jointly manage and direct the subjects online through the mobile application Medical Weight Management in real time
Self-monitoring group:Physicians, nutritionists, and health managers monthly provide the subjects weight loss programs and face-to-face guidance
the subjects do self-monitoring during the visit interphase

Sponsors

The First Affiliated Hospital, Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-50 years; 2. BMI=28.0kg/m2; 3. Agree to eat meals and exercise on time, monitor and record relevant indicators in accordance with the program requirements throughout the study; 4. Capable of using smartphones and operating the mobile application "Medical Weight Management".

Exclusion criteria

Exclusion criteria: 1. Patients with gastrointestinal diseases accompanied by malabsorption; 2. In the stage of active liver diseases, or with obvious liver function damage, wich is defined as alanine aminotransferase (ALT) > 2.5 times the normal upper limit; 3. A history of unstable or rapidly progressive renal disease or renal impairment, which is defined as serum creatinine = 133 mol/L (1.5mg/dl) in male subjects or = 125 mol/L (1.4mg/dl) in female subjects; 4. Diagnosed with diabetes, Obesity caused by Cushing syndrome and other endocrinology diseases; 5. Patients who have taken the following drugs within the last 4 weeks: hypoglycemic drugs, lipid-lowering drugs (such as statins, betts, etc.), diet drugs, liver protection drugs, glucocorticoids, and drugs that may affect blood glucose, blood lipids, pancreatic islet function and other indicators; 6. patients who have performed weight-reduction surgery; 7. Patients with mental disorders, unwillingness to communicate with others or language barrier, leading to insufficient understanding of the research program or incapability to cooperation with researchers; 8. Patients with severe cardiopulmonary insufficiency, hypothyroidism or malignant tumors; 9. Women who are pregnant, or who are planning to be pregnant during the study, or who have the ability to be pregnant but refuse to use effective, medically approved contraception during the study, or who are breastfeeding; 10. With a history of alcoholism, the amount of alcohol consumed by men = 140g per week, and that of women = 70g; 11. Physical dysfunction, affecting aerobic exercise and resistance exercise; 12. Those who are currently participating in other weight loss programmes or have lost more than 5 per cent of their body weight in the past six months; 13. Patients with poorly controlled severe hypertension, i.e., systolic blood pressure = 180mmHg and/or diastolic blood pressure = 110mmHg; Patients with systolic blood pressure <95mmHg.

Design outcomes

Primary

MeasureTime frame
Body Mass Index (BMI);body weight;

Secondary

MeasureTime frame
Serum Lipid;Index of glucose metabolism;Index of inflammation;human components;metabolic rate;liver fat content;measurements of neck, waist and hip;PCSK9;blood pressure;islet function;routine urine test;

Countries

China

Contacts

Public ContactHongwen Zhou

The first Affiliated Hospital of Nanjing Medical University

drhongwenzhou@163.com+86 13605143818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026